Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 11:57 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 472 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Skin Testing Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Nanocytology Test to Evaluate Skin Cancer in High Risk Patients

NCT01905891
View directory record Official record
Conditions
Actinic Keratosis, Squamous Cell Carcinoma
Interventions
Superficial shave biopsy
Procedure
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 89 Years
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 19, 2014 · Synced Oct 20, 2026, 11:57 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Pilot Evaluation of Two Test Materials With a Positive Control When Used as a Patient Preoperative Skin Preparation

NCT03861780
View directory record Official record
Conditions
Bacteria Microflora Reduction
Interventions
Project X 26ml, Project X 5.1ml, Prevantics Maxi Swabstick
Drug
Lead sponsor
Professional Disposables International, Inc.
Industry
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Bozeman, Montana
Source: ClinicalTrials.gov public record
Updated Oct 22, 2021 · Synced Oct 20, 2026, 11:57 AM EDT
Recruiting Phase 2 Interventional

A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer

NCT07054190
View directory record Official record
Conditions
Breast Cancer
Interventions
Inavolisib, Ribociclib, Letrozole, Giredestrant
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older · Female only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
4
States / cities
Los Angeles, California • Orange, California • Germantown, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 20, 2026, 11:57 AM EDT
Terminated Phase 2 Interventional Results available

Genetic Testing in Predicting Response to Paclitaxel in Women With Breast Cancer

NCT00088829
View directory record Official record
Conditions
Breast Cancer
Interventions
Paclitaxel, microarray analysis, biopsy, neoadjuvant therapy
Drug · Genetic · Procedure
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older · Female only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2012
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jul 11, 2018 · Synced Oct 20, 2026, 11:57 AM EDT
Completed Not applicable Interventional Results available

Sleep Innovations for Preschoolers With Arthritis (SIPA): Developing and Pilot Testing of a Self-Management Intervention

NCT04354337
View directory record Official record
Conditions
Juvenile Idiopathic Arthritis
Interventions
Sleep Innovations for Preschoolers with Arthritis (SIPA)
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
2 Years to 5 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 10, 2025 · Synced Oct 20, 2026, 11:57 AM EDT
Recruiting Phase 3 Interventional

Testing Laser Therapy for Treatment of Vaginal Dryness in Survivors of Breast Cancer, The Revitalize Trial

NCT05379153
View directory record Official record
Conditions
Vaginal Atrophy, Breast Carcinoma
Interventions
Laser Therapy, Sham Intervention, Questionnaire Administration, Quality of Life Assessment
Device · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
22 Years and older · Female only
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
3
States / cities
Des Moines, Iowa • Ann Arbor, Michigan • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 20, 2026, 11:57 AM EDT
Active, not recruiting Phase 2 Interventional

Testing the Combination of Two Anticancer Drugs M1774 (Tuvusertib) and Avelumab to Evaluate Their Safety and Effectiveness in Treating Merkel Cell Skin Cancer, MATRiX Trial

NCT05947500
View directory record Official record
Conditions
Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8, Locally Advanced Merkel Cell Carcinoma, Metastatic Merkel Cell Carcinoma, Refractory Merkel Cell Carcinoma, Unresectable Merkel Cell Carcinoma
Interventions
Avelumab, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography, Tuvusertib
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
50
States / cities
Irvine, California • La Jolla, California • Los Angeles, California + 39 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 20, 2026, 11:57 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Head-to-Head Comparison Study Between Different FDA Registered Allergy Skin Test Applicators

NCT07400718
View directory record Official record
Conditions
Allergy, Hypersensitivity, Immediate, Ig-E Mediated Food
Interventions
AllerTest-10 Multi-Head Skin Test Device, Skintestor OMNI Multi-Head Skin Test Device, Multi-Test II Multi-Head Skin Test Device, AllerTest-8 Multi-Head Skin Test Device
Device
Lead sponsor
QHSLab, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Oct 20, 2026, 11:57 AM EDT
Terminated Phase 2 Interventional Results available

A Clinical Study to Test Long Term Safety of GLPG1690 for Patients With Systemic Sclerosis

NCT03976648
View directory record Official record
Conditions
Systemic Sclerosis
Interventions
GLPG1690
Drug
Lead sponsor
Lakefront Biotherapeutics NV
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
6
States / cities
Los Angeles, California • Boca Raton, Florida • Ann Arbor, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2022 · Synced Oct 20, 2026, 11:57 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Decision Support for BRCA Testing in Ethnically Diverse Women

NCT03470402
View directory record Official record
Conditions
Breast Cancer, BRCA1 Mutation, BRCA2 Mutation, Ovarian Cancer
Interventions
RealRisks, BNAV, iNYP, Standard Educational Material, High-Risk Message
Other
Lead sponsor
Columbia University
Other
Eligibility
21 Years to 75 Years · Female only
Enrollment
276 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 19, 2021 · Synced Oct 20, 2026, 11:57 AM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

A 21-Day Topical Safety Study of Diltiazem Hydrochloride Using a Cumulative Irritant Patch Test Design

NCT01821274
View directory record Official record
Conditions
Skin Irritation
Interventions
Diltiazem Hydrochloride 2% Cream, Vehicle Cream, 0.1% solution o sodium lauryl sulfate (SLS), Saline 0.9%
Drug
Lead sponsor
Ventrus Biosciences, Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Paramus, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 21, 2013 · Synced Oct 20, 2026, 11:57 AM EDT
Completed Phase 1 Interventional

Assessment of Residual Allergenicity of Grass/Rye Pollen Allergoid Using Skin Prick Testing

NCT00104390
View directory record Official record
Conditions
Type I Hypersensitivity
Interventions
Grass MATA MPL
Biological
Lead sponsor
Allergy Therapeutics
Industry
Eligibility
18 Years to 50 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jun 10, 2010 · Synced Oct 20, 2026, 11:57 AM EDT
Withdrawn Not applicable Interventional

Comparison of the Quantiferon®-TB GOLD (in Tube) Assay With Tuberculin Skin Testing for Detecting Latent Tuberculosis Infection in Patients With Chronic Liver Disease Being Evaluated for or Awaiting Liver Transplantation

NCT00424684
View directory record Official record
Conditions
Chronic Liver Disease, TB
Interventions
collection of blood sample
Procedure
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 7, 2020 · Synced Oct 20, 2026, 11:57 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Skin Sensitization Test (Modified Draize-95 Test)

NCT03886987
View directory record Official record
Conditions
Skin Sensitisation
Interventions
Blue Non Sterile Powder Free Nitrile Examination Gloves
Device
Lead sponsor
Central Medicare Sdn. Bhd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
245 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Fairfield, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 22, 2019 · Synced Oct 20, 2026, 11:57 AM EDT
Completed No phase listed Observational

Pancreatic Cancer Early Detection Program

NCT02206360
View directory record Official record
Conditions
Pancreatic Cancer, Pancreas Cancer, Pancreatic Adenocarcinoma, Familial Pancreatic Cancer, BRCA 1/2, HNPCC, Lynch Syndrome, Hereditary Pancreatitis, FAMMM, Familial Atypical Multiple Mole Melanoma, Peutz Jeghers Syndrome
Interventions
Endoscopic Ultrasound, Magnetic Resonance Imaging (MRI)
Procedure
Lead sponsor
White Plains Hospital
Other
Eligibility
18 Years and older
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
1
States / cities
White Plains, New York
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 20, 2026, 11:57 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Testing Use of Topical Imipramine in Reducing Ultraviolet B Induced Microvesicle Particle Release in Photosensitive Subjects

NCT04520217
View directory record Official record
Conditions
Photosensitivity, Microvesicle Particle
Interventions
4% Imipramine Cream, Base Cream
Drug
Lead sponsor
Wright State University
Other
Eligibility
18 Years to 50 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Fairborn, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 27, 2025 · Synced Oct 20, 2026, 11:57 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

EXoPERT EMERALD Clinical Study

NCT07186296
View directory record Official record
Conditions
Breast Cancer, Colon Cancer, Pancreatic Cancer, Ovarian Cancer, Lung Cancer
Interventions
EXoPred
Diagnostic Test
Lead sponsor
EXoPERT
Industry
Eligibility
45 Years and older
Enrollment
1,400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
9
States / cities
Long Beach, California • Los Angeles, California • Honolulu, Hawaii + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 20, 2026, 11:57 AM EDT
Completed Phase 1 Interventional Results available

This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer

NCT03099174
View directory record Official record
Conditions
Neoplasms, Breast Neoplasms
Interventions
Xentuzumab, Abemaciclib, Letrozole, Anastrozole, Fulvestrant
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
6
States / cities
Santa Monica, California • New Haven, Connecticut • Miami, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2025 · Synced Oct 20, 2026, 11:57 AM EDT
Completed Not applicable Interventional

Breast Cancer Pre-habilitation and Prospective Surveillance to Prevent, Detect, and Optimize Physical and Function

NCT06081127
View directory record Official record
Conditions
Breast Cancer
Interventions
MOve-ABC, Enhanced Usual Care
Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Female only
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 30, 2025 · Synced Oct 20, 2026, 11:57 AM EDT
Completed Not applicable Interventional

OPTimizing Treatment Focused Genetic Testing IN Cancer

NCT04066361
View directory record Official record
Conditions
Breast Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer
Interventions
Chatbot, Video Education
Other
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
301 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 25, 2024 · Synced Oct 20, 2026, 11:57 AM EDT
Completed Phase 2 Interventional Results available

A Study to Characterize the Pharmacokinetics, Pharmacodynamics, and Safety of Anifrolumab in Adult Type I Interferon Test High Systemic Lupus Erythematosus Subject With Active Skin Manifestations

NCT02962960
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Anifrolumab, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 70 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
6
States / cities
Thousand Oaks, California • Orlando, Florida • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2023 · Synced Oct 20, 2026, 11:57 AM EDT
Terminated Phase 2 Interventional Results available

A Study to Test Long-term Treatment With Spesolimab in People With Palmoplantar Pustulosis (PPP) Who Took Part in Previous Studies With Spesolimab

NCT04493424
View directory record Official record
Conditions
Palmoplantar Pustulosis
Interventions
Spesolimab
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
6
States / cities
Birmingham, Alabama • Columbia, Missouri • East Windsor, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Oct 20, 2026, 11:57 AM EDT
Completed Phase 2 Interventional

A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors

NCT02576431
View directory record Official record
Conditions
Solid Tumors Harboring NTRK Fusion
Interventions
BAY2757556 (Larotrectinib, Vitrakvi)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
215 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
18
States / cities
Palo Alto, California • Santa Monica, California • Pembroke Pines, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 20, 2026, 11:57 AM EDT
Completed No phase listed Observational

Systemic Reactions to Allergen Immunotherapy Amd Skin Testing

NCT00594802
View directory record Official record
Conditions
SYSTEMIC REACTION
Interventions
Not listed
Lead sponsor
University of South Florida
Other
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Aug 9, 2010 · Synced Oct 20, 2026, 11:57 AM EDT